share_log

We Think That There Are More Issues For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Than Just Sluggish Earnings

We Think That There Are More Issues For Sichuan Hezong Medicine Easy-to-buy Pharmaceutical (SZSE:300937) Than Just Sluggish Earnings

我們認爲,四川合衆藥易購藥業(深交所股票代碼:300937)面臨的問題不僅僅是收益疲軟
Simply Wall St ·  05/01 18:38

The subdued market reaction suggests that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd.'s (SZSE:300937) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, investors should be aware of some other underlying weaknesses in the numbers.

疲軟的市場反應表明,四川合宗醫藥易購藥業有限公司s(深圳證券交易所代碼:300937)最近的收益沒有任何意外。我們的分析表明,除了疲軟的利潤數字外,投資者還應意識到這些數字中的其他一些潛在弱點。

earnings-and-revenue-history
SZSE:300937 Earnings and Revenue History May 1st 2024
SZSE: 300937 2024 年 5 月 1 日的收益和收入歷史記錄

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

For anyone who wants to understand Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥7.9m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. We ran the numbers on most publicly listed companies worldwide, and it's very common for unusual items to be once-off in nature. And that's as you'd expect, given these boosts are described as 'unusual'. If Sichuan Hezong Medicine Easy-to-buy Pharmaceutical doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

對於任何想了解四川合衆藥易購藥業在法定數字之外的利潤的人來說,值得注意的是,在過去的十二個月中,從價值790萬元人民幣的不尋常物品中獲得了法定利潤。雖然我們希望看到利潤增加,但當不尋常的物品做出重大貢獻時,我們往往會更加謹慎一些。我們統計了全球大多數上市公司的數字,不尋常的物品在自然界中很常見。這正如你所預料的那樣,因爲這些增強被描述爲 “不尋常”。如果四川合宗藥業易購藥業沒有看到這種捐款重演,那麼在其他條件相同的情況下,我們預計其利潤將在本年度下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對四川合宗醫藥易購藥業的資產負債表分析。

Our Take On Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's Profit Performance

我們對四川合衆藥易購藥業盈利表現的看法

Arguably, Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. While conducting our analysis, we found that Sichuan Hezong Medicine Easy-to-buy Pharmaceutical has 3 warning signs and it would be unwise to ignore these.

可以說,四川合宗藥業易購藥業的法定收益被提高利潤的不尋常項目所扭曲。正因爲如此,我們認爲四川合衆藥易購藥業的法定利潤可能好於其基礎盈利能力。不幸的是,在過去的十二個月中,其每股收益有所下降。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。請記住,在分析股票時,值得注意所涉及的風險。在進行分析時,我們發現四川合衆藥易購藥業有三個警告信號,忽視這些信號是不明智的。

Today we've zoomed in on a single data point to better understand the nature of Sichuan Hezong Medicine Easy-to-buy Pharmaceutical's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

今天,我們放大了單一數據點,以更好地了解四川合衆藥易購藥業利潤的性質。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份免費收藏的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論